MHLW Reports Little Progress In Japan’s Generic Drug Use
This article was originally published in PharmAsia News
Executive Summary
Ministry of Health Labor and Welfare Minister Yoichiro Masuzoe and Treasury Minister Shoichi Nakagawa Dec. 18 announced a plan of reducing ¥220 billion in social insurance growth for fiscal year 2009, in which the real reduction will come from ¥23 billion as a result of generic drug use. However, a report released Dec. 15 by MHLW painted a discouraging picture of generic drug use in Japan, even amidst several pushes from the ministry to promote usage during the year.
You may also be interested in...
Japan Vows Anew To Overcome Reluctance To Boost Generics Use
Despite slow adoption, the potential for massive shift in Japan’s branded-generics market is a draw for foreign firms as policymakers see increased usage as key to containing health costs.
Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War
Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo
Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War
Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo